Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
11 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
104 rhumatos / 100 000 hab. — département bien doté
21 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
7
7 articles ont été cités au moins 7fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
321
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
30
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
6
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Immune dysregulation through longitudinal lymphocyte trajectories and their clinical determinants in hospitalized COVID-19 patients
2026ArticleIntensive Care Medicine Experimental
At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods
2024ArticleScientific Reports
High frequency of severe liver dysfunction in critically ill Dengue patients in the French West Indies
2024ArticleJournal of Intensive Medicine
Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms
2024ArticleHeliyon
Sex differences in post-acute neurological sequelae of SARS-CoV-2 and symptom resolution in adults after coronavirus disease 2019 hospitalization: an international multi-centre prospective observational study
2024ArticleBrain Communications
Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19
2023ArticleJAMA Network Open
Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study
2023ArticleJournal of Neurology
Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19
2023ArticleKidney International Reports
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
C.H.U. DE POINTE-A-PITRE/ABYMES
BP 465, 97139 LES ABYMES
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of the International AIDS Society · 2014
IntroductionPatients with HIV infection are at increased risk of developing cardiovascular disease (CVD) due to complex interactions between traditional CVD risk factors, antiretroviral therapy (ART) and HIV infection itself [1]. Prevention of CVD is essential as it remains the most common serious non‐AIDS event and contributes significantly to all‐cause mortality. A cardiovascular risk‐assessment model tailored to HIV population is thus essential.Materials and MethodsWe conducted a retrospective case‐control study within the HIV cohort of the Saint‐Pierre Hospital, Brussels. Cases (n=73) presented a first CVD (ischemic heart disease or stroke) between January 2002 and December 2012. Controls (n=142) were patients without any CVD and were matched for age, race, sex and follow‐up duration. We used Wilcoxon test to identify predictors of cardiovascular risk among the data collected. We compared Framingham [2] and DAD (Data Collection on Adverse Events of anti‐HIV drugs) [3] equations calculated in all patients at time of event, two, four and six years before. We then simulated the impact on the DAD scores if different therapeutic interventions had been introduced when patient cardiovascular risk at ten years exceeded 20%.ResultsComparison of cases and controls showed that C‐reactive protein (CRP) >3 mg/L (p=0.008) and HIV viral load >50 copies/ml (p=0.007) at time of event, as well as slower increase in CD4 cell count (p=0.035), were significantly more frequent in cases. DAD and Framingham median scores in cases and controls are shown in Figure 1 and Table 1. Smoking cessation lowered the DAD score of cases at time of event from 21.6% to 18.3%, modification of ART (discontinuation of indinavir, lopinavir and abacavir) lowered it from 21.6% to 17%, while both interventions with control of blood pressure and cholesterol lowered it from 21.6% to 12.4%.ConclusionsIncreased CRP levels, uncontrolled HIV viral load at time of event and slower immunologic response were found to be associated with increased CVD risk. DAD score in cases increased more and faster over time than the Framingham score and seems therefore to be more accurate in identifying HIV‐positive patients at high risk of CVD. Different therapeutic interventions could have led to a significant reduction of the DAD score in these patients and should remain a priority in patient management.
European journal of case reports in internal medicine · 2020
The serological prevalence of Epstein-Barr virus (EBV) among young adults exceeds 90% worldwide. Even though EBV primary infection is usually benign, severe complications can occur in adolescents and young adults and so the disease must be promptly diagnosed. The development of an oropharyngeal abscess leading to a descending necrotizing mediastinitis (DNM) is exceptional and potentially lethal, so early diagnosis with a CT scan, appropriate antibiotics and surgery are essential. The authors present a case where DNM was associated with reactive hemophagocytic syndrome as a result of infectious mononucleosis, as well as a review of similar cases in the English literature.
Transplant infectious disease : an official journal of the Transplantation Society · 2024
AbstractBackgroundDespite the burden of pyelonephritis after kidney transplantation, there is no consensus on initial empirical antibiotic management.MethodsWe surveyed clinicians throughout the world on their practice and opinions about the initial empirical therapy of post‐transplant pyelonephritis, using clinical vignettes. A panel of experts from 19 countries on six continents designed this survey, and invited 2145 clinicians to participate.ResultsA total of 721 clinicians completed the survey (response rate: 34%). In the hypothetical case of a kidney transplant recipient admitted with pyelonephritis but not requiring intensive care, most respondents reported initiating either a 3rd‐generation cephalosporin (37%) or piperacillin‐tazobactam (21%) monotherapy. Several patient‐level factors dictated the selection of broader‐spectrum antibiotics, including having a recent urine culture showing growth of a resistant organism (85% for extended‐spectrum ß‐lactamase‐producing organisms, 90% for carbapenemase‐producing organisms, and 94% for Pseudomonas aeruginosa). Respondents attributed high importance to the appropriateness of empirical therapy, which 87% judged important to prevent mortality. Significant practice and opinion variations were observed between and within countries.ConclusionHigh‐quality studies are needed to guide the empirical management of post‐transplant pyelonephritis. In particular, whether prior urine culture results should systematically be reviewed and considered remains to be determined. Studies are also needed to clarify the relationship between the appropriateness of initial empirical therapy and outcomes of post‐transplant pyelonephritis. image
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Medical mycology · 2026 · Journal Article
Thomas C, Boullé C, Claude PA, Claudeon J, et al.
Transplant infectious disease : an official journal of the Transplantation Society · 2024 · Journal Article
Cachera L, Oehler E, Abdelmoumen K, Tardieu L, et al.
Transplant infectious disease : an official journal of the Transplantation Society · 2024 · Journal Article
Coussement J, Bansal SB, Scemla A, Svensson MHS, et al.
Journal of intensive medicine · 2024 · Journal Article
Camous L, Markowicz S, Loraux C, Jabot J, et al.
Critical care medicine · 2023 · Observational Study
Pommier JD, Martino F, Delamare F, Jarrige B, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022 · Journal Article
Viel S, Markowicz S, Ait-Medjber L, Ouissa R, et al.
European journal of case reports in internal medicine · 2020 · Journal Article
Van Noten H, Markowicz S, Cappeliez S, Cherifi S
Sexually transmitted diseases · 2014 · Case Reports
Markowicz S, Anstey JR, Hites M, Montesinos I, et al.
European journal of case reports in internal medicine · 2020 · Journal Article
Van Noten H, Markowicz S, Cappeliez S, Cherifi S
Sexually transmitted diseases · 2014 · Case Reports
Markowicz S, Anstey JR, Hites M, Montesinos I, et al.
Open forum infectious diseases · 2026 · Journal Article
Pizzinat C, Bastian S, Desmoulins F, Curlier E, et al.
Journal of the International AIDS Society · 2014 · Journal Article
Markowicz S, Delforge M, Necsoi C, De Wit S
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022 · Journal Article
Markowicz S, Trioux T, Rulquin C, Le Guillou C, et al.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).